Form PTO 1390 U.S. DEPARTMENT OF COM (REV 5-93)	IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER PU60030					
TRANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/542811						
INTERNATIONAL APPLICATION NO. PCT/US2004/002425	INTERNATIONAL FILING DATE 29 January 2004	PRIORITY DATE CLAIMED 30 January 2003					
TITLE OF INVENTION QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS							
APPLICANT(S) FOR DO/EO/US Jeffrey K. KERNS, Qi JIN, Hongxing YAN, Zehong WAN							
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and							

other information:

1	[x]	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3.	[x]	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).					
4.	[x]	The US has been elected (Article 31).					
5.	[x]	A copy of the International Application as filed (35 U.S.C. 371(c)(2))					
		a. [] is transmitted herewith (required only if not transmitted by the International Bureau).b. [] has been transmitted by the International Bureau.					
		c. [x] is not required, as the application was filed in the United States Receiving Office (RO/US).					
6.	[]	A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
7.	[]	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. [] are transmitted herewith (required only if not transmitted by the International Bureau). b. [] have been transmitted by the International Bureau. c. [] have not been made; however, the time limit for making such amendments has NOT expired. d. [] have not been made and will not be made.					
8.	[]	A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)).					
9.	[]	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10.	[]	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
	Items 11. to 16. below concern other document(s) or information included:						
11.	[x]	An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.					

- 12. [] An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- 13. [x] A FIRST preliminary amendment.

(Add claim to priority via Preliminary Amendment for US originating cases only)

- 14. [] A SECOND or SUBSEQUENT preliminary amendment.
- 15. [] A substitute specification.
- 16. [x] Power of attorney and Correspondence Address Indication Form
- 17. [x] An Abstract on a separate sheet of paper.
- 18. [x] Copy of Form PCT/ISA/210.
- 19. [x] Other items or information: Copy of Assignment, Statement Under 37 CRF 3.73(b)

US APPLICATION NO. (if known see 37 CFR 1.50)			INTERNATIONAL APPLICATION NO. PCT/US2004/002425		ATTORNEYS DOCKET NO. PU60030	
	llowing fees are submi	CALCULATION	PTO USE ONLY			
	National Fee (37 C.F					
■ Basic I	Filing Fee	\$300.00				
	nation Fee					
	al Preliminary Examinat					
	isions of PCTArtlice33(1	\$200.00				
	ations					
■ Search						
	37 CFR 1.445(a)(2) has b			:		
		\$100.00	\$100.00			
	Search Report prepared					
*All other situ	ations	\$600.00				
2 1 5412			/E CALCULATIONS =		-	
	0.00 for furnishing the earliest claimed priorit	\$0.00				
Claims	Number Filed	Number Extra	Rate			
Total claims	12 - 20 =	0	0 x \$50.00	\$0.00		
Independent claims	1 - 3 =	0	0 x \$200.00	\$0.00		
Multiple depende	ent claims (if applicabl	e)	+ \$360.00	\$0.00		
		\$600.00				
	pplication size fee - fo 0 addt'l sheets 1 x \$25	\$0.00				
		\$600.00				
Processing fee of	\$130.00 for furnishing					
☐ 20 ☐ 30 mon	ths from the earliest cl					
		\$600.00				
		Amount to be	\$			
		refunded				
				charged	\$600.00	
a.	ck in the amount of \$	to cover the abo	ove fees is enclosed.			

- b. \square Please charge my Deposit Account No. <u>19-2570</u> in the amount of <u>\$600.00</u> to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7339
Facsimile (610) 270-5090

SIGNATURE
Laura K. Madden
NAME
48,352
REGISTRATION NO.

10/542811 JC12 Rec'd PCT/PTC 20 JUL 2005

PATENT ATTORNEY'S DOCKET NUMBER PU60030

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/US2004/002425 2

29 January 2004

30 January 2003

TITLE OF INVENTION

QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS

APPLICANT(S) FOR DO/US

Jeffrey K. KERNS, Qi JIN, Hongxing YAN, Zehong WAN

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450

ATTENTION: DO/US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date <u>July 20, 2005</u> in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EV453421638US</u> addressed to the:

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)

20462

CUSTOMER NUMBER